Shares of Nyxoah plunged 14.8% to $0.95 in pre-market trading after the Belgian medtech company slashed its 2026 revenue guidance to €33–35 million from €36–40 million, a cut announced alongside preliminary Q3 results released at 8:00 a.m. ET. The downgrade comes less than a month after Nyxoah reaffirmed that very same guidance during a September CFO transition, making the reversal especially jarring for a stock already down ~80% from its 52-week high.

  • The Numbers Don't Lie: Growth Is There, But Not Enough. Q3 global net revenue came in at approximately €9.2 million, with U.S. revenue of roughly €6.7 million — up 29% sequentially. That sounds strong in isolation. But add Q1's €6.4 million and Q2's €7.7 million, and the first nine months total only about €23.3 million — meaning Nyxoah needs roughly €10–12 million in Q4 just to hit the bottom of the new range. As recently as August, the company maintained the €36–40 million target. The midpoint of guidance effectively dropped ~12% in under three months.

  • A CFO Exit and an Immediate Guidance Cut Raise Red Flags. On September 21, Nyxoah disclosed that CFO John Landry would step down effective October 2 to "pursue another professional opportunity," while simultaneously reaffirming full-year guidance. The company reaffirmed worldwide net revenue expectations of €36–40 million at that time. Seventeen days later, the guidance was cut. That sequence erodes management credibility at a moment when investor trust is critical.

  • The Cash Burn Clock Is Ticking. Cash, cash equivalents, and financial assets stood at approximately €77 million as of September 30. That's down from €97.8 million at the end of Q2.

Operating losses ran €20.6 million in Q2 alone and €41.1 million for the first half. At roughly €20 million per quarter in losses, the current cash pile may last into mid-2027 — but only if the company doesn't accelerate spending. Management has said it "will continue to explore additional financing options, including the public or private issuance of equity." At a market cap now hovering near $100 million, any equity raise would be severely dilutive.

  • A Bright Spot Buried in the Bad News. Nyxoah's pivotal study in a broader patient population — those with complete concentric collapse — met its primary efficacy and safety endpoints.

A supplemental application has been submitted to the FDA to expand the device's U.S. indication. If approved, this could meaningfully expand the addressable patient pool. But label expansion takes time, and the stock's brutal slide suggests investors aren't willing to wait.